Intercure Ltd. (INCR) stock
INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.61−0.02 (-0.55%)
Close on Nov 17, 2026Market cap $197.40MP/E –Yield –
Intercure revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was 270.20M ILS, up 13.1% from the year before. The highest annual figure on record is 388.68M ILS in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 270.20M ILS | +13.1% |
| FY2024 | Dec 31, 2024 | 238.85M ILS | -32.8% |
| FY2023 | Dec 31, 2023 | 355.55M ILS | -8.5% |
| FY2022 | Dec 31, 2022 | 388.68M ILS | +76.9% |
| FY2021 | Dec 31, 2021 | 219.68M ILS | +237.8% |
| FY2020 | Dec 31, 2020 | 65.04M ILS | +628.6% |
| FY2019 | Dec 31, 2019 | 8.93M ILS | – |
See a number that looks wrong?